|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Page 414 AMPA/kainate receptors, 243, 244, 287, 290 Amputation, 247, 250 Amytrophic lateral sclerosis (ALS), 13, 14, 115, 330, 339, 365 treatment, 283, 285, 286, 287, 289, 300, 305, 366, 367 Anergix, 394 Animal models, ix , 84, 90-104, 396 bone marrow transplants, 296 brain, 96, 103 encephalomyelitis, 7, 43, 72-73, 84-86, 99; see also Experimental autoimmune encephalomyelitis (EAE) demylenation, 7, 91-99 (passim), 102-103, 357 immune system, general, 7, 21, 48, 91, 97, 103 magnetic resonance imaging, 262 major histocompatibility complex (MHC), 91, 103 neurons, 6, 7, 95 remyelination, 243-244 research recommendations, 4, 6-7, 356-358 spasticity, 131 T cells, autoreactive, 251-252, 355 tolerance strategies, 21 transgenic, 91, 93, 97, 100-104, 280, 355, 356-357 transplantation, 292 viruses, 21, 91, 357-358 mouse hepatitis virus (MHV), 95, 98-100 Theiler's murine encephalomyelitis virus (TMEV), 48, 91, 92, 95-98, 99, 269, 357 Antegren, 294 Antibiotics, 407 Antibodies, 42, 68, 255, 349, 350, 394, 410 see also Antigens; Immunoglobulins; Vaccines autoantibodies, 66, 73, 74, 92, 93, 251, 255, 266, 355 neutralizing, beta-interferon, 51, 52, 97 T cells, antigen-specific, 60, 70, 93, 252-253, 254, 257-258, 260, 263-265, 279, 280, 354, 355, 397 Antigens, 60, 68, 263 see also Major histocompatibility complex astrocytes, 244-245, 350 autoantigens, 5-6, 7, 42, 44, 45, 50, 60, 66, 67, 71-74 (passim), 82, 88, 91, 93, 100, 244, 251-255, 257, 279, 280, 354, 355, 357, 398 superantigens, 67, 92, 93, 95, 254 cerebrospinal fluid (CSF), 42, 45 neutralizing antibodies, 51, 52, 97 Anxiety, 122, 123, 152, 200, 211, 217, 224 see also Depression side effects of treatment, 50, 125, 126, 127, 135, 388 treatment, 227, 229 Apoptosis, 7, 98, 243, 254, 255, 259, 269, 281, 284-285, 286, 287, 295, 351, 358-359, 392 Arthritis, 14, 44, 69, 122, 145, 152, 153, 297, 299, 328, 329, 337, 366 Asians, 48, 77, 79, 83, 85, 87 Assistive technology, ix , 199, 205-210, 385-386 catheterization, 143, 206 cognitive impairment, 119, 209 cost and cost-effectiveness, 205, 206, 207, 210 defined, 205 employment, 193, 207-208 environmental control technology, 206, 207 health screening, 222-223 insurance coverage, 206, 209, 222 wheelchairs, 128, 188, 199, 206-207, 209, 220, 222, 386 Astrocytes, 3, 4 antigens, 244-245, 350 biological features of MS, 45, 62, 64, 71, 87 blood-brain barrier, 257 cytokines, 257, 258, 259, 350 disease mechanism research, 241, 245, 253, 257, 258, 259, 267 glial scars, 3, 241, 350 inflammation, 258 research recommendations, 241, 244-245, 253, 257, 258, 259, 267, 349, 350 treatment, 282, 284, 286, 294 Asymptomatic MS, 6, 30, 35-36, 88, 115, 177 Ataxia and tremor, 128, 138-140, 163 assistive technologies, 209 employment and, 191 experimental autoimmune encephalomyelitis (EAE) vs MS, 92
|
|
|||||||||||||||
